quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

OSB GROUP PLC - Transaction in Own Shares

View original at globenewswire.com
OSB GROUP PLC - Transaction in Own Shares OSB GROUP PLC ISIN: GB00BLDRH360 28 January 2026 LEI number: 213800ZBKL9BHSL2K459 OSB GROUP PLC (the “Company”) Transaction in Own Shares The Company announces that on 27 January 2026 it had purchased a total of 129,500 of its ordinary shares of £0.01 each (the "ordinary shares…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • No ordinary shares are held in treasury. Therefore, the total number of voting rights in the Company is 354,846,712

    80% confidence

  • Following settlement of the above purchases and cancellation of the purchased ordinary shares, the Company's total number of ordinary shares in issue shall be 354,846,712 ordinary shares

    80% confidence

Data points we hold from this source

OSB GROUP PLC · total voting rights354846712 voting_rights
OSB GROUP PLC · stock price low lse616.50 GBp
OSB GROUP PLC · stock price vwap cboe bxe619.49 GBp
OSB GROUP PLC · stock price vwap lse625.09 GBp
OSB GROUP PLC · stock price low cboe bxe616.50 GBp
OSB GROUP PLC · stock price high lse633.50 GBp
OSB GROUP PLC · stock price high cboe bxe626.50 GBp
OSB GROUP PLC · shares purchased lse90000 shares
OSB GROUP PLC · shares purchased cboe bxe39500 shares
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
OSB GROUP PLC - Transaction in Own Shares — Source | Via News | pt.VIA.NEWS